Home Up Call me back Contents Immunology Infectious agents Cellular Biology Molecular biology Instruments Chimical Product NEW antibodiesHIV p24 HTLV SIV HIV p24

Google

       Pricelist 2010 

redcoon BelgiŽ GENTAUR BVBA

VAT BE0473327336

Av. de l Armee 68 B4

1040 Brussels BELGIUM

  Tel + 32 16 58 90 45 

Fax + 32 16 50 90 45

GENTAUR France SARL

SIRET 48423788800017

Rue Lagrange, 9

75005 Paris, France

 Tel 01 43 25 01 50

Fax 01 43 25 01 60 

GENTAUR Germany

52074 Aachen, Germany

 Tel 0241 40 08 90 86

Fax 0241 55 91 05 36

GENTAUR Pol Sp. Z.o.o. Ulica Ogarna 15/19B m2

80-826 GDANSK

Tel 00 48 51 760 77 08

Fax: 00 32 16 50 90 45

GENTAUR Italy

23015 Milano, Italy

 Tel 02 36 00 65 93

Fax 02 36 00 65 94

ČeskŠ republika Praha
+420246019719
 

Danmark

+4569918806 

Finland Helsset
+358942419041

Ελλάς Αθήνα
+302111768494
 

Ireland Dublin
+35316526556
 

Luxembourg
+35220880274
 

MagyarorszŠg Budapest
+3619980547
 

Nederland
+31208080893
 

Norge Oslo
+4721031366
 

÷sterreich
+43720880899
 

Sverige Stockholm
+46852503438
 

Schweiz ZŁri
+41435006251
 

 

Northern America 

Canada Montreal
+15149077481
 

US New York
+17185132983

 

Other Countries redcoon BelgiŽ
0032 (0)16 41 44 07

 

HIV p24 Antigen ELISA References

Journal references for ZMC's HIV p24 Antigen ELISA Kit

Baba M, Takashima K, Miyake H, et al. TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans. Antimicrob Agents Chemother. 2005; 49 (11): 4584-4591.

Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral Gene Transfer of Rpe65 Rescues Survival and Function of Cones in a Mouse Model of Leber Congenital Amaurosis. PLoS Med. 2006; 3 (10): e347.

Blancou P, Evans DT, Desrosiers RC. PRA1 co-localizes with envelope but does not influence primate lentivirus production, infectivity or envelope incorporation. Journal of General Virology. 2005; 86: 1785-1790.

Caceda R, Kinkead B, Owens M, et al. Virally Mediated Increased Neurotensin 1 Receptor in the Nucleus Accumbens Decreases Behavioral Effects of Mesolimbic System Activation. The Journal of Neuroscience. 2005; 25 (50): 11748-11756.

Emori Y, Ikeda T, Ohashi T, et al. Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virology. 2004; 85: 2603-2613.

Fang J, Kubota S, Pomerantz RJ. A Trans-Dominant Negative HIV Type 1 Rev with Intact Domains of NLS/NOS and NES. AIDS Research and Human Retroviruses. 2002; 18 (10): 705-709.

Finnegan CM, Rawat SS, Puri A, et al. Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci U S A. 2004; 101 (43): 15452-15457.

Forthal DN, Landucci G, Daar ES. Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells. J Virol. 2001; 75 (15): 6953-6961.

Forthal DN, Landucci G, Phan TB, et al. Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J Virol. 2005; 79 (4): 2042-2049

Hamer DH, Bocklandt S, McHugh L, et al. Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication. J Virol. 2003; 77 (19): 10227-10236.

Ikeda T, Nishitsuji H, Zhou X, et al. Evaluation of the Functional Involvement of Human Immunodeficiency Virus Type 1 Integrase in Nuclear Import of Viral cDNA during Acute Infection. J Virol . 2004; 78 (21): 11563-11573.

Jiang YH, Emau P, Cairns S, et al. SPL7013 Gel as a Topical Microbicide for Prevention of Vaginal Transmission of SHIV89.6P in Macaques. AIDS Research and Human Retroviruses. 2005; 21 (3): 207-213.

Kamada K, Igarashi T, Martin MA, et al. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A. 2006; 103 (45): 16959-16964.

Kameoka M, Nukuzuma S, Itaya A, et al. RNA Interference Directed against Poly(ADP-Ribose) Polymerase 1 Efficiently Suppresses Human Immunodeficiency Virus Type 1 Replication in Human Cells. J Virol. 2004; 78 (16): 8931-8934.

Kawano Y, Yoshida T, Hieda K, et al. A Lentiviral cDNA Library Employing Lambda Recombination Used To Clone an Inhibitor of Human Immunodeficiency Virus Type 1-Induced Cell Death. J Virol. 2004; 78 (20): 11352-11359.

Kino T, Gragerov A, Slobodskaya O, et al. Human Immunodeficiency Virus Type 1 (HIV-1) Accessory Protein Vpr Induces Transcription of the HIV-1 and Glucocorticoid-Responsive Promoters by Binding Directly to p300/CBP Coactivators. J Virol. 2002; 76 (19): 9724-9734.

Kobayashi M, Takaori-Kondo A, Shindo K, et al. APOBEC3G Targets Specific Virus Species. J Virol. 2004; 78 (15): 8238-8244.

Komoto S, Tsuji S, Ibrahim MS, et al. The Vpu Protein of Human Immunodeficiency Virus Type 1 Plays a Protective Role against Virus-Induced Apoptosis in Primary CD4 + T Lymphocytes. J Virol. 2003; 77 (19): 10304-10313.

Lawrence DMP, Durham LC, Schwartz L, et al. Human Immunodeficiency Virus Type 1 Infection of Human Brain-Derived Progenitor Cells. J Virol. 2004; 78 (14): 7319-7328.

Marodon G, Klatzmann D. In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors. BMC Immunology. 2004; 5: 18.

McGettigan JP, Naper K, Orenstein J, et al. Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. J Virol. 2003; 77 (20): 10889-10899.

McGettigan JP, Pomerantz RJ, Siler CA, et al. Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic. J Virol. 2003; 77 (1): 237-244.

McGettigan JP, Sarma S, Orenstein JM, et al. Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector. J Virol. 2001; 75 (18): 8724-8732.

Miyauchi K, Komano J, Yokomaku Y, et al. Role of the Specific Amino Acid Sequence of the Membrane-Spanning Domain of Human Immunodeficiency Virus Type 1 in Membrane Fusion. J Virol. 2005; 79 (8): 4720-4729.

Nishikawa M, Takashima K, Nishi T, et al. Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5. Antimicrob Agents Chemother. 2005; 49 (11): 4708-4715.

Nishitsuji H, Kohara M, Kannagi M, et al. Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration. J Virol. 2006; 80 (15): 7658-7666.

Nitanda T, Wang X, Kumamoto H, et al. Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine In Vitro. Antimicrob Agents Chemother. 2005; 49 (8): 3355-3360.

Oruetxebarria I, Venturini F, Kekarainen, et al. p 16INK4a Is Required for hSNF5 Chromatin Remodeler-induced Cellular Senescence in Malignant Rhabdoid Tumor Cells. J. Biol. Chem. 2004; 279 (5): 3807-3816.

Sakuragi J, Iwamoto A, Shioda T. Dissociation of Genome Dimerization from Packaging Functions and Virion Maturation of Human Immunodeficiency Virus Type 1. Journal of Virology. 2002; 76 (3): 959-967.

Sakuragi J, Ueda S, Iwamoto A, et al. Possible Role of Dimerization in Human Immunodeficiency Virus Type 1 Genome RNA Packaging. J Virol. 2003; 77 (7): 4060-4069.

Shoya Y, Tokunaga K, Sawa H, et al. Human topoisomerase I promotes HIV-1 proviral DNA synthesis: Implications for the species specificity and cellular tropism of HIV-1 infection. PNAS. 2003; 100 (14): 8442-8447.

Smulevitch S, Michalowski D, Zolotukhin AS, et al. Structural and Functional Analysis of the RNA Transport Element, a Member of an Extensive Family Present in the Mouse Genome. J Virol. 2005; 79 (4): 2356-2365.

Takashima K, Miyake H, Furuta RA, et al. Inhibitory Effects of Small-Molecule CCR5 Antagonists on Human Immunodeficiency Virus Type 1 Envelope-Mediated Membrane Fusion and Viral Replication. Antimicrob Agents Chemother. 2001; 45 (12): 3538-3543.

Takashima K, Miyake H, Kanzaki N, et al. Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist. Antimicrob Agents Chemother. 2005; 49 (8): 3474-3482.

Tomiyama H, Akari H, Adachi A, et al. Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8 + T-Cell Cytolytic Activity and Cytokine Production. J Virol. 2002; 76 (15): 7535-7543.

Trushin SA, Bren GD, Asin S, et al. Human Immunodeficiency Virus Reactivation by Phorbol Esters or T-Cell Receptor Ligation Requires both PKCőĪ and PKCőł. J Virol. 2005; 79 (15): 9821-9830.

Yokomaku Y, Miura H, Tomiyama H, et al. Impaired Processing and Presentation of Cytotoxic-T-Lymphocyte (CTL) Epitopes Are Major Escape Mechanisms from CTL Immune Pressure in Human Immunodeficiency Virus Type 1 Infection. J Virol. 2004; 78 (3): 1324-1332.

Yonezawa A, Morita R, Takaori-Kondo A, et al. Natural Alpha Interferon-Producing Cells Respond to Human Immunodeficiency Virus Type 1 with Alpha Interferon Production and Maturation into Dendritic Cells. J Virol. 2003; 77 (6): 3777-3784.

Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2002; 99 (10): 7015-7020.

Zhang C, Chen Y, Ben K. An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma. BMC Infect Dis. 2003; 3: 30.

Zhang XY, La Russa VF, Jakob Reiser J. Transduction of Bone-Marrow-Derived Mesenchymal Stem Cells by Using Lentivirus Vectors Pseudotyped with Modified RD114 Envelope Glycoproteins. J Virol. 2004; 78 (3): 1219-1229.